Urate crystals alone are required but not sufficient to trigger gout flares; they can also be modulated by environmental, metabolic, genetic and epigenetic factors. Avoiding large variation in urate levels, maintaining prophylaxis until crystal clearance and initiating low-dose urate-lowering therapy are efficient strategies for disease management.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Major, T. J. et al. A genome-wide association analysis reveals new pathogenic pathways in gout. Nat. Genet. 56, 2392–2406 (2024).
Stewart, S., Maxwell, H. & Dalbeth, N. Prevalence and discrimination of OMERACT-defined elementary ultrasound lesions of gout in people with asymptomatic hyperuricaemia: A systematic review and meta-analysis. Semin. Arthritis Rheum. 49, 62–73 (2019).
Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29–42 (2017).
Kelly, B. et al. Relationship between serum urate and changes in dual-energy CT monosodium urate crystal volume over 1 year in people with gout: an individual participant data analysis. Ann. Rheum. Dis. 84, 136–142 (2025).
Doherty, M. et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392, 1403–1412 (2018).
Popov, D., Jain, L., Alhilali, M., Dalbeth, N. & Poulsen, R. C. Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare. FASEB J. 37, e22940 (2023).
Stamp, L. K. et al. Predicting gout flares in people starting allopurinol using the start-low go-slow dose escalation strategy. Arthritis Care Res. 76, 1371–1378 (2024).
Christ, A. et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 172, 162–175.e14 (2018).
Ames, B. N., Cathcart, R., Schwiers, E. & Hochstein, P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl Acad. Sci. USA. 78, 6858–6862 (1981).
Acknowledgements
The authors would like to thank their colleagues who contributed to the discussions in this Comment.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ea, H.K., Richette, P. Factors beyond urate levels for managing gout flares. Nat Rev Rheumatol 21, 371–372 (2025). https://doi.org/10.1038/s41584-025-01255-4
Published:
Issue date:
DOI: https://doi.org/10.1038/s41584-025-01255-4